Coronary Artery Disease
Stable Ischemic Heart Disease — Supply, Demand, and the Primacy of Medical Therapy
Stable coronary artery disease — also called stable ischemic heart disease (SIHD) — is the condition in which fixed atherosclerotic narrowing of one or more coronary arteries reduces blood flow to the heart muscle enough to cause symptoms, usually during exertion. The heart muscle does not get enough oxygen when demand rises; the patient feels chest pressure; they stop; it goes away. That cycle, reliably reproducible and reliably relieved by rest, is the clinical signature of stable angina pectoris.[1] Ischemic heart disease causes more deaths and disability, and incurs greater economic costs, than any other illness in the developed world. In the United States alone, approximately 15.5 million people have ischemic heart disease, and roughly 3.4 million adults over age 40 have angina pectoris. The landmark ISCHEMIA trial — the largest trial ever conducted in stable CAD — settled the central management question: for most patients with stable symptoms and even moderate-to-severe ischemia on stress testing, optimal medical therapy is not inferior to an initial invasive strategy for preventing death or myocardial infarction.[2] Understanding that finding — what it means and what it does not — is the intellectual core of managing this condition.
In 1768, William Heberden stood before the College of Physicians in London and described, with clinical precision that has barely been improved upon in 250 years, a syndrome he called “angina pectoris” — a sense of strangling and anxiety in the chest, almost always brought on by walking, especially uphill or after a meal, and relieved promptly by standing still. Heberden had no theory for what caused it. He was simply watching, and reporting. His description — the pressure, the radiation to the left arm, the reliable relationship to exertion — still defines the clinical diagnosis today. He observed twenty patients with the syndrome over many years, most of them men over fifty, and noted that several died suddenly during ordinary activity. He did not know what was happening inside their arteries. But he knew it was serious.
For the next century, the connection between Heberden’s angina pectoris and the coronary arteries remained largely theoretical. Anatomists had described calcified, hardened coronary arteries in elderly patients at autopsy, but the clinical significance was debated. In 1879, Thomas Brunton first used amyl nitrite to relieve an anginal attack, reasoning that dilating blood vessels might help. William Murrell extended this to nitroglycerin the same year. They were right in practice before they were right in theory: nitrates relieve angina primarily by reducing preload and decreasing myocardial oxygen demand, not simply by dilating the obstructed vessel. Their empirical success bought decades of relative therapeutic optimism before anyone seriously asked whether the underlying obstruction itself needed to be addressed.
For most of the twentieth century, the dominant view was that coronary artery disease was fundamentally a plumbing problem: the arteries were too narrow, and the solution was to open them. Coronary artery bypass grafting, pioneered in the 1960s, was transformative for patients with left main or severe three-vessel disease. Balloon angioplasty, introduced by Andreas Grüntzig in 1977, seemed to promise a minimally invasive solution for everyone else. By the late 1990s, PCI had become one of the most common elective procedures in medicine, with millions of stents placed annually in patients with stable angina. The assumption was that if a narrowing was there, opening it should help. That assumption met its reckoning in 2007.
The COURAGE trial randomized 2,287 patients with stable CAD and objective ischemia to PCI plus optimal medical therapy versus optimal medical therapy alone.[3] There was no significant difference in death or MI at 4.6 years. Then in 2020, ISCHEMIA — which enrolled 5,179 patients with moderate-to-severe ischemia and excluded left main disease — confirmed and extended COURAGE: a routine invasive strategy did not reduce the composite of cardiovascular death, MI, hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest.[2] The statin revolution, meanwhile, had been quietly doing what stents could not. The 4S trial in 1994 demonstrated that simvastatin reduced coronary mortality by 42% in patients with established CAD.[4] Medicine — not metal — changed the natural history of this disease.
The myocardium is metabolically one of the most demanding tissues in the body. At rest, the heart already extracts roughly 70–80% of the oxygen delivered to it — which means, unlike skeletal muscle, it cannot compensate for increased workload simply by extracting more oxygen. The only way to increase oxygen delivery to the heart is to increase coronary blood flow. That is why coronary blood flow normally rises fourfold during strenuous exercise.[1]
Atherosclerosis disrupts this system in a specific way. When a plaque reduces the diameter of a coronary artery by 50%, there is no resting ischemia, but the ability to increase flow during exercise is impaired. When the diameter is reduced by 80%, even resting flow may be compromised. The heart muscle downstream is starved of oxygen. The result is ischemia — a state in which myocardial oxygen demand exceeds supply. The patient feels it as chest pressure, typically substernal, often radiating to the left arm or jaw, lasting 2–5 minutes, and consistently relieved by rest or nitroglycerin.[1]
Atherosclerosis does not develop uniformly. It clusters at branch points in the epicardial arteries — the left anterior descending (LAD), right coronary artery (RCA), and left circumflex (LCx) — where turbulent blood flow damages the endothelium. The loss of endothelial function is the initiating event: without intact endothelium, the vessel wall loses its anticoagulant, anti-inflammatory, and vasodilatory properties. Monocytes adhere, penetrate the subintima, engulf oxidized LDL, and become foam cells. Over years to decades, a subintimal collection of lipid, smooth muscle cells, inflammatory cells, and extracellular matrix grows into a plaque. Hurst’s pathological classification distinguishes fibroatheromas (stable plaques with a thick fibrous cap and well-contained necrotic core) from thin-cap fibroatheromas (TCFAs) — plaques with a fibrous cap thinner than 65 μm, a large necrotic core, and heavy macrophage infiltration.[5] Stable CAD, clinically, reflects fixed fibrocalcific obstruction — plaques that do not rupture but do narrow the lumen enough to limit flow during exercise.
Two distinct ischemic mechanisms operate in stable CAD. Demand ischemia is the classic form: a fixed stenosis limits maximum achievable flow, and when the heart’s metabolic demands exceed what can be delivered through the narrowed vessel, ischemia ensues. This is the mechanism behind exercise-induced angina. Supply ischemia results from dynamic changes in coronary tone superimposed on a fixed lesion — vasoconstriction triggered by endothelial dysfunction, catecholamine surges, or cold exposure. This explains why some patients have variable angina thresholds: they can walk a mile at noon but cannot walk a block first thing in the morning. Coronary microvascular disease — dysfunction of the small resistance arteries without significant epicardial obstruction — accounts for a substantial minority of stable angina, particularly in women, and is detectable only with invasive coronary reactivity testing.
During an ischemic episode, the sequence of events is predictable and tells you what to look for with imaging. First, perfusion falls. Then regional wall motion abnormalities appear — the ischemic segment stops contracting normally. Then the ECG changes. Finally, angina symptoms emerge. This “ischemic cascade” is why stress echocardiography can detect ischemia even without ST changes, and why wall motion is a more sensitive marker of ischemia than chest pain alone.
The Canadian Cardiovascular Society (CCS) classification provides a standardized language for quantifying angina severity. It maps closely to the NYHA functional classification and is the primary tool for tracking treatment response and determining when medical therapy has failed.[1]
| Class | Description | Clinical Examples |
|---|---|---|
| I | Ordinary physical activity does not cause angina. Angina only with strenuous, rapid, or prolonged exertion at work or recreation. | Running, heavy lifting, intense athletics. Walking and climbing stairs without symptoms. |
| II | Slight limitation of ordinary activity. Angina with walking more than 2 blocks on level ground or climbing more than 1 flight of stairs at a normal pace. | Brisk walking, walking uphill, walking after meals, in cold weather, or under emotional stress. |
| III | Marked limitation of ordinary physical activity. Angina with walking 1–2 blocks or climbing 1 flight of stairs. | Dressing, slow walking indoors, light housework may provoke symptoms. |
| IV | Inability to carry on any physical activity without discomfort. Angina may be present at rest. | Rest angina; any activity causes symptoms. Urgent evaluation and revascularization planning required. |
Any of these features requires urgent evaluation — do not manage as stable outpatient disease. Accelerating angina (CCS class increasing rapidly over days), angina at rest lasting more than 20 minutes, new-onset severe angina (CCS III–IV within 2 months), angina with resting ST depression or T-wave inversion, angina associated with diaphoresis, nausea, or hemodynamic instability — these patterns suggest unstable angina or NSTEMI. The distinction between stable and unstable CAD is not just semantic: it changes the urgency of revascularization, the choice of antiplatelet therapy, and the immediate risk of MI. When in doubt, treat as ACS until proven otherwise.
The physical examination of a patient with stable CAD is frequently — even characteristically — normal between episodes. What the exam gives you is not a diagnosis but a risk profile and a search for competing causes of symptoms. The classic angina history in a middle-aged man with multiple risk factors already carries an extremely high pre-test probability for significant CAD. The exam confirms the prior probability and screens for complications.[1]
| Finding | Sensitivity | Specificity | Clinical Pearl |
|---|---|---|---|
| Classic angina history (substernal pressure, exertional, relieved by rest) | ~90% for CAD in men >50 | Moderate | Best diagnostic tool available; positive LR approaches 10 in high-risk patients |
| Exercise ECG (ST depression ≥1 mm) | ~75% | ~85% | False-negatives common with circumflex disease; false-positives in LVH, digoxin, LBBB |
| Exercise echo — new wall motion abnormality | ~85% | ~88% | More sensitive than ECG alone; identifies the territory and extent of ischemia |
| Nuclear perfusion imaging (SPECT/PET) | ~87% | ~73% | Quantifies ischemic burden; >10% ischemic myocardium predicts mortality benefit from revascularization |
| CT coronary angiography | ~95% | ~83% | High NPV; excludes CAD effectively; best in intermediate pre-test probability |
| S4 gallop during ischemia | ~30% | High | Indicates reduced LV compliance; marker of diastolic dysfunction from chronic ischemia |
| Xanthelasmas / xanthomas | Low | High | Markers of hypercholesterolemia; clue to familial hyperlipidemia as underlying driver |
Stress testing is the backbone of the diagnostic evaluation after history and resting ECG. For patients with interpretable ECGs and adequate exercise capacity, the standard Bruce treadmill protocol is the starting point. High-risk features on stress testing — ischemia at low workload (before stage II of Bruce), ST depression >2 mm, ST depression in multiple leads, prolonged recovery ST depression, or a fall in systolic BP during exercise — warrant expedited coronary angiography regardless of symptom severity.[1]
Standard cardiac views for CAD assessment: Obtain parasternal long-axis (PLAX), parasternal short-axis (PSAX) at mid-papillary level, apical four-chamber, and apical two-chamber views with the phased-array probe. The LV should appear football-shaped in PLAX — any deviation suggests pathology. In the PSAX view, you are looking at the LV in cross-section; a well-functioning LV should contract symmetrically, with all walls moving inward and thickening uniformly. Focal wall motion abnormalities — segments that hypokinese (move less), are akinetic (do not move), or are dyskinetic (bulge outward in systole) — are the primary POCUS finding in CAD.[6]
Coronary territory mapping: The LAD supplies the anterior wall, anterior septum, and apex. The RCA supplies the inferior wall and right ventricle. The LCx supplies the lateral wall. A wall motion abnormality in a specific territory tells you which vessel is likely affected before you see the cath report. An anterior wall motion abnormality in a patient with chest pain means LAD disease until proven otherwise.
Resting wall motion abnormalities as a scar marker: A resting wall motion abnormality that is akinetic — no movement at all, even at rest — almost always represents prior myocardial infarction with established scar. Thinned myocardium (<6 mm in PSAX) with akinesis is consistent with transmural scar and has a very low likelihood of functional recovery after revascularization. Hand-carried ultrasound studies have confirmed that trained clinicians can detect wall motion abnormalities at the bedside with accuracy approaching formal laboratory echocardiography.[7]
POCUS in stable CAD serves several practical clinical roles beyond initial diagnosis. A bedside cardiac scan gives you a rapid assessment of LV systolic function, identifies prior infarction territory, and detects complications like LV aneurysm or significant mitral regurgitation from papillary muscle dysfunction — all in minutes, at the bedside.
Laboratory evaluation in stable CAD serves two purposes: quantifying the modifiable risk factors driving atherosclerosis progression, and identifying comorbidities that worsen ischemia or complicate therapy.[1]
| Test | Clinical Role & Interpretation |
|---|---|
| Fasting lipid panel | LDL <70 mg/dL is the target in established CAD; <55 mg/dL in very high-risk patients (recurrent events or multiple risk factors). LDL drives the atherogenic process — the lower, the better, with no established floor below which further reduction is harmful. Check HDL (low HDL independently predicts events) and non-HDL cholesterol. Repeat 4–12 weeks after initiating or changing statin therapy to confirm adherence and response. |
| HbA1c / fasting glucose | Diabetes accelerates coronary atherosclerosis and multiplies cardiovascular risk. Undiagnosed diabetes is common in CAD patients. HbA1c >6.5% warrants diabetic management. SGLT2 inhibitors and GLP-1 receptor agonists have additive cardiovascular benefits in diabetic patients with CAD, independent of glucose control. |
| hsCRP | High-sensitivity CRP (0–3 mg/L) is an independent predictor of coronary events, most useful for reclassifying intermediate-risk patients. An hsCRP >2 mg/L in a patient with borderline LDL strengthens the case for statin therapy. The JUPITER trial demonstrated that rosuvastatin reduces events even in patients with near-normal LDL when hsCRP is elevated. |
| Coronary artery calcium (CAC) score | CT-based Agatston scoring quantifies coronary calcification. A CAC of 0 provides powerful reassurance in intermediate-risk patients — the 10-year event rate is very low and statins can often be withheld. A CAC >300 (or >75th percentile for age/sex) identifies patients who benefit from statin therapy even when global risk scores suggest intermediate risk. MESA data show CAC predicts events better than any single traditional risk factor. |
| Resting 12-lead ECG | Q waves identify prior transmural MI by territory. LVH suggests long-standing hypertension with adverse remodeling. LBBB precludes standard ST-analysis on stress ECG. Resting ST-T changes indicate ongoing ischemia or prior injury. A normal resting ECG in a patient with classic angina does not reduce the probability of significant CAD. |
| Renal function / eGFR | CKD accelerates cardiovascular disease and must be identified before initiating ACE inhibitors or contrast for coronary angiography. Microalbuminuria is an independent cardiovascular risk marker. eGFR is required before any invasive procedure and for dosing antiplatelet agents. |
Managing stable CAD involves three parallel tracks: eliminating or controlling the risk factors that drive disease progression, relieving angina symptoms to improve quality of life, and — where appropriate — revascularizing to prevent MI or death. The ISCHEMIA trial established that for most patients, the first two tracks can be accomplished without revascularization.[2]
| Intervention | When & How | Evidence & Key Points |
|---|---|---|
| High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) | All patients with established CAD, indefinitely. Target LDL <70 mg/dL; <55 mg/dL in very high-risk patients. Check LFTs at baseline; routine monitoring not required unless symptomatic. | 4S trial: simvastatin reduced all-cause mortality 30% and coronary mortality 42% over 5.4 years in patients with established CAD.[4] WOSCOPS demonstrated primary prevention benefit with pravastatin.[9] |
| Aspirin 81 mg/day | All patients with established CAD without contraindication. Enteric-coated formulation preferred. Clopidogrel 75 mg/day is an acceptable substitute if aspirin is not tolerated. | Irreversible cyclooxygenase inhibition reduces platelet aggregation. Meta-analyses show 25% RRR in vascular events in secondary prevention. Risk of GI bleeding increases with dose — 81 mg is adequate.[1] |
| ACE inhibitor or ARB | All CAD patients with hypertension, diabetes, or reduced EF (<40%). Consider in all stable CAD patients even with normal LV function. Start at low dose, titrate to target. | HOPE trial: ramipril 10 mg/day reduced the composite of MI, stroke, or CV death by 22% in high-risk patients, many without reduced EF or hypertension.[10] |
| Beta-blocker (metoprolol succinate, atenolol, bisoprolol) | Class I for CCD with LVEF ≤50%, angina, arrhythmia, or hypertension. Titrate to resting HR 55–60 bpm. For patients >1 year post-MI with preserved EF and no other indication: 2023 guidelines downgraded to Class IIb — re-evaluate need based on comorbidities rather than continuing indefinitely. | The 2023 CCD guideline marks a significant shift: routine long-term beta-blocker use is no longer supported in post-MI patients with preserved EF beyond 1 year. Evidence for mortality benefit in this group is weak; side effects (fatigue, depression, sexual dysfunction) warrant reassessment. Still first-line when LVEF ≤50% or angina is present.[11] |
| Sublingual nitroglycerin (SL NTG 0.4 mg) | All patients with angina should carry SL NTG. Instruct to use at onset of angina AND prophylactically 5 minutes before activities likely to provoke symptoms. Repeat up to 3 times, 5 minutes apart; if chest pain persists, call 911. | Nitrates reduce LV preload, decrease wall tension and oxygen demand, and dilate epicardial coronary vessels. Relief of angina within 1–5 minutes confirms ischemic etiology; failure to respond raises concern for ACS or non-cardiac chest pain.[1] |
| Long-acting nitrates (isosorbide mononitrate) | Add for persistent angina despite beta-blocker. Use eccentric dosing (e.g., 7 AM and 2 PM) to allow an 8–10 hour nitrate-free interval daily and prevent tolerance. Do NOT combine with phosphodiesterase-5 inhibitors (sildenafil, tadalafil) — risk of severe hypotension. | Reduces anginal frequency and increases exercise tolerance. Tolerance develops rapidly with continuous administration; eccentric dosing is mandatory.[1] |
| Calcium channel blockers (amlodipine, diltiazem) | Add to beta-blocker for refractory angina, or use as monotherapy when beta-blockers are contraindicated (asthma, severe COPD, AV block). Dihydropyridines (amlodipine) are preferred in combination; avoid verapamil plus beta-blocker — excessive bradycardia risk. | As effective as beta-blockers for angina relief. Do not use short-acting nifedipine as monotherapy — reflex tachycardia may worsen ischemia.[1] |
| PCI (percutaneous coronary intervention) | Indicated when symptoms are unacceptable despite optimal medical therapy and anatomy is suitable, or when stress testing shows large ischemic territory (>10% LV myocardium). Not indicated for asymptomatic patients with stable CAD simply to prevent MI — this is what ISCHEMIA settled. | COURAGE (2007): PCI + OMT not superior to OMT alone for death or MI at 4.6 years.[3] ISCHEMIA (2020): same conclusion in larger sample with more severe ischemia.[2] |
| CABG (coronary artery bypass grafting) | Preferred over PCI when: left main disease (>50% stenosis); three-vessel disease with reduced EF (<50%) or diabetes; two-vessel disease including proximal LAD with reduced EF. Internal mammary artery grafts to the LAD have 90%+ patency at 10 years. | CABG improves survival in left main disease and three-vessel disease with LV dysfunction — a survival benefit not replicated by PCI in these anatomic subsets. This is where revascularization demonstrably changes prognosis.[1] |
| Colchicine 0.5 mg once daily | Consider in all CCD patients for secondary prevention, particularly those with residual inflammatory risk (elevated hsCRP despite statin therapy). Added to the 2023 guideline as Class IIa. Low dose; GI intolerance is the most common side effect. Hold before elective procedures. | LoDoCo2 (2020): colchicine 0.5 mg/day reduced the composite of cardiovascular death, MI, stroke, or ischemia-driven revascularization by 31% (HR 0.69) in stable CAD over a median 28.6 months. COLCOT (2019) showed similar benefit early post-MI. First anti-inflammatory agent with proven cardiovascular outcome benefit in CCD.[11] |
| Recommendation — AHA/ACC 2023 Chronic Coronary Disease Guideline[11] | Class | Level | Key Point |
|---|---|---|---|
| High-intensity statin therapy in all CCD patients; LDL <70 mg/dL; consider <55 mg/dL in very high-risk | I | A | Add ezetimibe or PCSK9i if above target |
| Aspirin 75–100 mg/day in all CCD patients without contraindication | I | A | Clopidogrel as substitute |
| Beta-blocker in CCD with LVEF ≤50%, angina, arrhythmia, or hypertension | I | A | Still Class I when LVEF ≤50% |
| Re-evaluate need for beta-blocker >1 year post-MI in patients with preserved EF and no other indication | IIb | B-R | Downgraded from Class I in 2012 |
| ACE inhibitor/ARB in CCD with hypertension, diabetes, or EF <40% | I | A | Ramipril or equivalent |
| Low-dose colchicine (0.5 mg/day) for secondary prevention in CCD | IIa | B-R | New in 2023; anti-inflammatory benefit |
| SGLT2 inhibitor or GLP-1 agonist in CCD with type 2 diabetes and high CV risk | I | A | New in 2023; independent of glucose control |
| Sublingual NTG for immediate relief of angina — patient education required | I | B | Prophylactic use emphasized |
| CABG for left main disease (>50%) or three-vessel disease with EF <50% | I | A | Survival benefit established |
| Routine PCI to reduce MI or death in patients with stable CCD well-controlled on OMT | III | A | No benefit shown; avoid |
| Annual influenza vaccination in all CCD patients | I | B | Reduces cardiovascular events |
The ORBITA trial (2018) is the most philosophically disruptive study in interventional cardiology in a generation. It randomized 200 patients with single-vessel stable angina and hemodynamically significant stenosis (confirmed by FFR or iFR) to PCI versus a sham procedure — real arterial access, heparinization, and catheter placement, but no balloon or stent — while keeping patients and assessors blinded to the assignment.[12] The primary outcome was exercise time increment at six weeks. PCI did not significantly improve exercise time compared to sham. Angina frequency decreased in both groups. The placebo effect of undergoing a cardiac procedure, it turns out, is substantial and real.
This finding does not mean PCI is useless in stable angina. It means something more precise: PCI’s benefit in stable angina is primarily — perhaps predominantly — symptomatic, and at least part of that symptomatic benefit is not specific to the mechanical restoration of coronary flow. ISCHEMIA confirms the mortality half of this argument: in 5,179 patients with moderate-to-severe ischemia on stress testing, followed for a median of 3.2 years, an initial invasive strategy did not reduce cardiovascular death, MI, hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest.[2] The invasive strategy did improve angina symptoms more quickly, but by three years the difference in symptom burden was negligible in the groups who were alive and followed.
The fellow-level synthesis: PCI in stable CAD is a quality-of-life intervention, not a life-prolonging one, for the vast majority of patients. That changes the risk-benefit calculus enormously. A patient with mild symptoms well-controlled on two antianginal agents does not need a stent. A patient with CCS class III angina despite maximally tolerated medical therapy, who is highly motivated to increase activity and understands the trade-offs, may get meaningful quality-of-life benefit from PCI — provided they understand the procedure is unlikely to make them live longer. Left main disease and severe three-vessel disease with reduced EF are the exceptions: these anatomic findings carry a mortality benefit with surgical revascularization that medical therapy alone cannot match. The clinical skill is knowing precisely which patient you are looking at.
The definitive trial establishing that optimal medical therapy is not inferior to an initial invasive strategy for preventing death or MI in stable CAD with moderate-to-severe ischemia (n=5,179).
First large trial to demonstrate PCI + OMT is not superior to OMT alone for death or MI in stable CAD. Challenged the dominant revascularization-first paradigm that had guided practice for a generation.
First double-blind, sham-controlled trial of PCI in stable single-vessel angina. PCI did not significantly improve exercise time vs. sham procedure at 6 weeks, revealing the substantial placebo component of symptom relief.
Proved that simvastatin reduces all-cause mortality (30%), coronary mortality (42%), and need for revascularization in patients with established CAD — establishing statins as the cornerstone of secondary prevention.
[1] Antman EM, Loscalzo J. Chapter 267: Ischemic Heart Disease. In: Jameson JL, et al., eds. Harrison’s Principles of Internal Medicine, 20th ed. McGraw-Hill, 2018.
[2] Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease (ISCHEMIA). N Engl J Med. 2020;382(15):1395–1407. PMID: 32227755. [PubMed]
[3] Boden WE, O’Rourke RA, Teo KK, et al. Optimal Medical Therapy With or Without PCI for Stable Coronary Disease (COURAGE). N Engl J Med. 2007;356(15):1503–1516. PMID: 17387127. [PubMed]
[4] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389. PMID: 7968073. [PubMed]
[5] Narula J, Virmani R, Narula N, Ibanez B, Fuster V. Chapter 16: Pathological Basis of Atherosclerotic Coronary Artery Disease. In: Fuster V, et al., eds. Fuster and Hurst’s The Heart, 15th ed. McGraw-Hill, 2022.
[6] Istrail L, et al. Chapter 17: Wall Motion Abnormalities & Myocardial Infarction. In: The POCUS Textbook. 2025.
[7] Spencer KT, Anderson AS, Bhargava A, et al. Physician-performed point-of-care echocardiography using a laptop platform compared with physical examination in the cardiovascular patient. J Am Coll Cardiol. 2001;37(8):2013–2018. PMID: 11419879. [PubMed]
[8] Picano E, Ciampi Q, Wierzbowska-Drabik K, et al. The new clinical standard of integrated quadruple stress echocardiography with ABCD protocol. Cardiovasc Ultrasound. 2018;16(1):22. PMID: 30285774. [PubMed]
[9] Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N Engl J Med. 1995;333(20):1301–1307. PMID: 7566020. [PubMed]
[10] Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE). N Engl J Med. 2000;342(3):145–153. PMID: 10639539. [PubMed]
[11] Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148(9):e9–e119. PMID: 37471501. [PubMed]
[12] Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. PMID: 29103656. [PubMed]